Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS Document date: 2018_12_19
ID: r79h9yzz_1205
Snippet: M. Musser Aratana Therapeutics, Inc. (coâ€distributor for EP4R antagonist, Galliprant, in the U.S.) †Receives research support (unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) †Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder). C. Johannes Aratana Therapeutics, Inc. (coâ€distributor for EP4R antagonist, .....
Document: M. Musser Aratana Therapeutics, Inc. (coâ€distributor for EP4R antagonist, Galliprant, in the U.S.) †Receives research support (unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) †Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder). C. Johannes Aratana Therapeutics, Inc. (coâ€distributor for EP4R antagonist, Galliprant, in the U.S.) †Former employee, speaking engagements, advisory board, consultant, receives honorarium, travel and research support (all unrelated to Galliprant). Elanco (primary distributor for EP4R antagonist, Galliprant, in the U.S.) †Receives research support (related to Galliprant but for different type of cancer, transitional cell carcinoma of the urinary bladder).
Search related documents:
Co phrase search for related documents- advisory board and consultant advisory board: 1
- advisory board and research support: 1, 2, 3, 4, 5, 6
- advisory board and research support travel: 1, 2, 3
- advisory board and speaking engagement: 1
- cancer different type and different type: 1, 2, 3, 4
- cell carcinoma and transitional urinary bladder cell carcinoma: 1, 2, 3, 4, 5
- cell carcinoma and urinary bladder: 1, 2, 3, 4, 5, 6, 7
- different type and research support: 1
Co phrase search for related documents, hyperlinks ordered by date